{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:01:29Z","timestamp":1746417689939,"version":"3.40.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Project of Wuhan Municipal Health Commission","award":["WX21Z70"],"award-info":[{"award-number":["WX21Z70"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Sacubitril\u2013valsartan has been shown to have superior effects over angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure (HF). However, the effects of sacubitril\u2013valsartan have never been systematically evaluated. Therefore, we performed a protocol for systematic review and meta-analysis to evaluate the efficacy and safety of sacubitril\u2013valsartan in patients with HF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We selected 8 databases, including PubMed, the Web of Science, Embase, Cochrane Library, the Chinese National Knowledge Infrastructure, the Chinese Science Journal Database, Wanfang Data, and the Chinese Biomedical Literature Database. The search time was from database establishment to March 2022. Two reviewers will screen the records and include quality studies according to inclusion criteria independently. Two reviewers will assess the risk of bias of the included studies by the \u201cRisk of Bias Assessment Tool\u201d of the Cochrane Handbook for randomized controlled trials. Statistical analysis will be performed with Review Manager software 5.3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A synthesis of current evidence of sacubitril\u2013valsartan for treating HF will be provided in this protocol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The results of this study will provide a theoretical basis for the clinical use of sacubitril\u2013valsartan to treat HF.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029149","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T19:13:30Z","timestamp":1654888410000},"page":"e29149","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Sacubitril\/Valsartan for heart failure"],"prefix":"10.1097","volume":"101","author":[{"given":"Wenqin","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6233-3677","authenticated-orcid":false,"given":"Xianli","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/j.2040-4603.2016.tb00669.x","article-title":"Pathophysiology of heart failure","volume":"6","author":"Tanai","year":"2015","journal-title":"Compr Physiol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0140-6736(18)31808-7","article-title":"Heart failure drug treatment","volume":"393","author":"Rossignol","year":"2019","journal-title":"Lancet"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.17219\/acem\/103669","article-title":"Advanced heart failure: a review","volume":"28","author":"Kepinska","year":"2019","journal-title":"Adv Clin Exp Med"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/ejhf.1629","article-title":"Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015","volume":"21","author":"Hao","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R05-20250504","doi-asserted-by":"crossref","DOI":"10.1136\/heartjnl-2021-320131","article-title":"Prevalence, incidence and survival of heart failure: a systematic review","author":"Emmons-Bell","year":"2022","journal-title":"Heart"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"f55","DOI":"10.1136\/bmj.f55","article-title":"Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis","volume":"346","author":"Chatterjee","year":"2013","journal-title":"BMJ"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1161\/CIRCHEARTFAILURE.114.001301","article-title":"Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction","volume":"7","author":"Patel","year":"2014","journal-title":"Circ Heart Fail"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2147\/IJGM.S310309","article-title":"Continuation of angiotensin converting enzyme inhibitors in acute heart failure","volume":"14","author":"AlHabeeb","year":"2021","journal-title":"Int J Gen Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jama.2012.452","article-title":"Association of treatment with losartan vs candesartan and mortality among patients with heart failure","volume":"307","author":"Svanstrom","year":"2012","journal-title":"JAMA"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10741-018-9757-1","article-title":"Practical guidance on the use of sacubitril\/valsartan for heart failure","volume":"24","author":"Sauer","year":"2019","journal-title":"Heart Fail Rev"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1161\/HYPERTENSIONAHA.117.10224","article-title":"Effect of sacubitril\/valsartan on exercise-induced lipid metabolism in patients with obesity and hypertension","volume":"71","author":"Engeli","year":"2018","journal-title":"Hypertension"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"e7034","DOI":"10.1161\/CIRCHEARTFAILURE.120.007034","article-title":"Efficacy and safety of Sacubitril\/Valsartan in high-risk patients in the PIONEER-HF trial","volume":"14","author":"Berg","year":"2021","journal-title":"Circ Heart Fail"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.recesp.2015.01.003","article-title":"Pathogenesis and clinical presentation of acute heart failure","volume":"68","author":"Ponikowski","year":"2015","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1824-7288-38-41","article-title":"Molecular pathogenesis of myocardial remodeling and new potential therapeutic targets in chronic heart failure","volume":"38","author":"Distefano","year":"2012","journal-title":"Ital J Pediatr"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:08:07Z","timestamp":1746328087000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029149"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":17,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029149","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"2022-03-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}